.

Megadeth's Dave Mustaine Completes Cancer Treatment 2019 In Review


William Lee | 01-03-2020

Share on Facebook Share on Twitter Pin it Share on Reddit email this article

Megadeth

Megadeth's Dave Mustaine Completes Cancer Treatment was a top 19 story of Oct. 2019: Megadeth cofounder David Ellefson says that his bandmate Dave Mustaine is currently in recovery after completing treatment for throat cancer and says they are very optimistic.

Ellefson revealed the news during an interview with Pomelo Rocker. He shared, "With Dave's throat cancer treatments that he has now completed, and he's just going through the recovery now, we're hopeful and optimistic about a full recovery for him with that.

"Once he's through that process, we're gonna just let that take as much time as it needs, and then we'll resume with the album. I'd like to hope maybe 2020 we'll be able to get a new album out...

"Sometime life throws you cards you didn't expect. Megadeth, we've always been a resilient band and we've always just worked around obstacles. Dave's a fighter, as we know. Just talking to him, he sounds very optimistic about the future for Megadeth."


Related Stories


Megadeth Reveal Ellefson's Replacement For Tour

Megadeth's New Album Will Be Turned In 'Any Day Now'

Megadeth Unplugged Album Being Released After 20 Years

Hatebreed Added To Megadeth and Lamb Of God Tour

Megadeth's New Album Will Not Include David Ellefson

Jason Newsted Joining Megadeth Rumor Addressed

David Ellefson Seeking Revenge Pornography Charges Against Leaker

Slipknot, Megadeth, Lamb Of God Lead Knotfest Lineup

Megadeth Fire David Ellefson Amid Allegations

Megadeth Address David Ellefson Controversy

More Megadeth News



advertisement

advertisement


Follow Us: Facebook Twitter Feeds

Contact Us - Privacy - antiMusic Email - Why we are antiMusic

Copyright© 1998 - 2021 Iconoclast Entertainment Group All rights reserved.

Please click here for legal restrictions and terms of use applicable to this site. Use of this site signifies your agreement to the terms of use.